{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"CAH","limit":50},"count":50,"signals":[{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":33,"context":"greement evidencing such transaction actually terminates. Material Acquisition means an Acquisition by the Company or one of its Subsidiaries for aggregate cash consideration of $500,000,000 or more. Material Adverse Effect means a material adverse effect on (a) the financial condition or results of operations of the Company and its Subsidiaries taken as a whole, (b)the ability of the Company to perform its obligations","filed_date":"2025-10-10","accession":"0000721371-25-000125","full_text":"https://origin.rootz.global/static/filing/0000721371-25-000125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":19,"context":"onal Seller, for itself andor on behalf of the Original Seller, a copy of such Letter of Credit and such error is material and no drawing has been made thereon prior to receipt of such notice (ix)any Material Adverse Effect (x)any breach of this Agreement or any other Transaction Document by any party thereto (xi)the bankruptcy or insolvency of any Seller Party, the Originator or any Affiliate of the foregoing (xii)the","filed_date":"2025-10-03","accession":"0000721371-25-000122","full_text":"https://origin.rootz.global/static/filing/0000721371-25-000122.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":42,"context":"sessment of Compensation Programs Management has assessed our compensation programs and concluded that our compensation policies and practices do not create risks that are reasonably likely to have a material adverse effect on Cardinal Health. This risk assessment included reviewing the design and operation of our compensation programs, identifying and evaluating situations or compensation elements that could raise more","filed_date":"2025-09-16","accession":"0000721371-25-000114","full_text":"https://origin.rootz.global/static/filing/0000721371-25-000114.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":21,"context":"ing the negative net working capital associated with the expired OptumRx contracts. We returned over $1.2 billion to shareholders in share repurchases ($750 million) and dividends ($494 million), and invested $547 million back into our businesses. We also deployed $5.3 billion for acquisitions, building out MSO platforms in Specialty that provide back-office support to physician practices and accelerating our at-Home","filed_date":"2025-09-16","accession":"0000721371-25-000114","full_text":"https://origin.rootz.global/static/filing/0000721371-25-000114.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":53,"context":"her product, and such approvals or registrations might not be granted on a timely basis, if at all. Any of these supply chain and quality-related events could be disruptive to our business and have a material adverse effect on operations, profitability, cash flows, and our financial condition.We could be subject to adverse changes in the tax laws or challenges to our tax positions. We are a large multinational corporati","filed_date":"2025-08-12","accession":"0000721371-25-000079","full_text":"https://origin.rootz.global/static/filing/0000721371-25-000079.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":8,"context":", Gastrologix, GastroGPO, and United Rheumatology. | $1.2 | | Divestitures We also complete divestitures from time to time, and we may explore additional divestitures in the future.  In June 2023, we signed a definitive agreement to contribute our Outcomes business to Transaction Data Systems (\"TDS\"), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a minority stake in the combined entity.","filed_date":"2025-08-12","accession":"0000721371-25-000079","full_text":"https://origin.rootz.global/static/filing/0000721371-25-000079.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":7,"context":"our condensed consolidated financial statements and report those consolidated results within our Pharma segment. Advanced Diabetes Supply Group (\"ADSG\")On November 11, 2024, we announced that we have entered into a definitive agreement to acquire the Advanced Diabetes Supply Group (\"ADSG\"), a diabetic medical supplies provider, for a purchase price of approximately $1.1 billion in cash, subject to certain adjustments. ADSG serves a","filed_date":"2025-01-30","accession":"0000721371-25-000013","full_text":"https://origin.rootz.global/static/filing/0000721371-25-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":33,"context":"nt evidencing such transaction actually terminates. Material Acquisition means the Acquisition by the Company or one of its Subsidiaries for aggregate cash consideration of $500,000,000 or more. -14- Material Adverse Effect means a material adverse effect on (a) the condition (financial or otherwise) or results of operations of the Company and its Subsidiaries taken as a whole, (b)the ability of the Company to perform i","filed_date":"2024-12-09","accession":"0000721371-24-000169","full_text":"https://origin.rootz.global/static/filing/0000721371-24-000169.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":34,"context":"reement evidencing such transaction actually terminates. Material Acquisition means the Acquisition by the Company or one of its Subsidiaries for aggregate cash consideration of $500,000,000 or more. Material Adverse Effect means a material adverse effect on (a) the condition (financial or otherwise) or results of operations of the Company and its Subsidiaries taken as a whole, (b)the ability of the Company to perform i","filed_date":"2024-10-10","accession":"0000721371-24-000112","full_text":"https://origin.rootz.global/static/filing/0000721371-24-000112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":32,"context":"sessment of Compensation Programs Management has assessed our compensation programs and concluded that our compensation policies and practices do not create risks that are reasonably likely to have a material adverse effect on Cardinal Health. This risk assessment included reviewing the design and operation of our compensation programs, identifying and evaluating situations or compensation elements  that could raise mor","filed_date":"2024-09-16","accession":"0000721371-24-000103","full_text":"https://origin.rootz.global/static/filing/0000721371-24-000103.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":18,"context":"| 41 | | | Related Person Transactions Policy and Process | 41 | | | Director Compensation | 42 | | | | | EXECUTIVE COMPENSATION | 44 | | | PROPOSAL 2 Advisory Vote to Approve the Compensation of Our Named Executive Officers | 45 | | | Compensation Discussion and Analysis | 46 | | | Human Resources and Compensation Committee Report | 62 | | | Executive Compensation Tables | 63 | | | Pay Ratio Disclosure | 76 | | | Pay V","filed_date":"2024-09-16","accession":"0000721371-24-000103","full_text":"https://origin.rootz.global/static/filing/0000721371-24-000103.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"margin_pressure","strength":100,"match_count":15,"context":"ponses may involve the implementation of measures which may not be as successful as intended in mitigating adverse impacts. Industry & Economic RisksWe could continue to suffer the adverse effects of competitive pressures.As described in greater detail in the \"Business\" section, we operate in markets that are highly competitive and dynamic. In addition, competitive pressures in each of our businesses may be increased","filed_date":"2024-08-14","accession":"0000721371-24-000056","full_text":"https://origin.rootz.global/static/filing/0000721371-24-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":43,"context":"her product, and such approvals or registrations might not be granted on a timely basis, if at all. Any of these supply chain and quality-related events could be disruptive to our business and have a material adverse effect on operations, profitability, cash flows, and our financial condition.We could be subject to adverse changes in the tax laws or challenges to our tax positions. We are a large multinational corporati","filed_date":"2024-08-14","accession":"0000721371-24-000056","full_text":"https://origin.rootz.global/static/filing/0000721371-24-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":14,"context":"Cordis business from Johnson & Johnson for $1.9 billion in October 2015. This divestiture also included Access Closure, Inc., a manufacturer and distributor of extravascular closure devices, that we acquired for approximately $320 million in May 2014.  | | | 28 | Cardinal Health | Fiscal 2024 Form 10-K | | | | | Business | | Customers | | | | Our largest customers, CVS Health and OptumRx, accounted for 24 percent and 17 per","filed_date":"2024-08-14","accession":"0000721371-24-000056","full_text":"https://origin.rootz.global/static/filing/0000721371-24-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":19,"context":"onal Seller, for itself andor on behalf of the Original Seller, a copy of such Letter of Credit and such error is material and no drawing has been made thereon prior to receipt of such notice (ix)any Material Adverse Effect 7 (x)any breach of this Agreement or any other Transaction Document by any party thereto (xi)the bankruptcy or insolvency of any Seller Party, the Originator or any Affiliate of the foregoing (xii)th","filed_date":"2023-11-03","accession":"0000721371-23-000084","full_text":"https://origin.rootz.global/static/filing/0000721371-23-000084.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":15,"context":"ssment of Compensation Programs** Management has assessed our compensation programs and concluded that our compensation policies and practices do not create risks that are reasonably likely to have a material adverse effect on Cardinal Health. This risk assessment included reviewing the design and operation of our compensation programs, identifying and evaluating situations or compensation elements that could raise more","filed_date":"2023-09-27","accession":"0001308179-23-001007","full_text":"https://origin.rootz.global/static/filing/0001308179-23-001007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":34,"context":"LLP |  37 | | |  Policy on Pre-Approval of Services Provided by Ernst& Young LLP |  37 | | |  |  | | |  EXECUTIVE COMPENSATION |  38 | | |  PROPOSAL 3 Advisory Vote to Approve the Compensation of Our Named Executive Officers |  39 | | |  PROPOSAL 4 Advisory Vote on the Frequency of Future Advisory Votes to Approve the Compensation of Our Named Executive Officers |  39 | | |  Compensation Discussion and Analysis |  40 |","filed_date":"2023-09-27","accession":"0001308179-23-001007","full_text":"https://origin.rootz.global/static/filing/0001308179-23-001007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"margin_pressure","strength":100,"match_count":16,"context":"of activist shareholders, may cause the market price for our shares to experience volatility, which could be significant. Industry & Economic Risks We could continue to suffer the adverse effects of competitive pressures. As described in greater detail in the \"Business\" section, we operate in markets that are highly competitive and dynamic. In addition, competitive pressures in our pharmaceutical and medical segment","filed_date":"2023-08-15","accession":"0000721371-23-000060","full_text":"https://origin.rootz.global/static/filing/0000721371-23-000060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":13,"context":"o the availability of insurance coverage for some matters described above, but the defense and resolution of current and future lawsuits and investigations are subject to uncertainty and could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity beyond the amounts accrued and beyond what we may be able to recover from our insurers. Additionally, laws governing insuran","filed_date":"2023-08-15","accession":"0000721371-23-000060","full_text":"https://origin.rootz.global/static/filing/0000721371-23-000060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":15,"context":"Cordis business from Johnson & Johnson for $1.9 billion in October 2015. This divestiture also included Access Closure, Inc., a manufacturer and distributor of extravascular closure devices, that we acquired for approximately $320 million in May 2014.  In August 2018, we completed the sale of our equity interest in naviHealth, Inc. to investor entities controlled by Clayton, Dubilier & Rice, LLC for proceeds of $737 million","filed_date":"2023-08-15","accession":"0000721371-23-000060","full_text":"https://origin.rootz.global/static/filing/0000721371-23-000060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":34,"context":"reement evidencing such transaction actually terminates. Material Acquisition means the Acquisition by the Company or one of its Subsidiaries for aggregate cash consideration of $500,000,000 or more. Material Adverse Effect means a material adverse effect on (a) the condition (financial or otherwise) or results of operations of the Company and its Subsidiaries taken as a whole, (b) the ability of the Company to perform","filed_date":"2023-03-02","accession":"0000721371-23-000014","full_text":"https://origin.rootz.global/static/filing/0000721371-23-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"margin_pressure","strength":100,"match_count":13,"context":"88bcfe40175c3f40a1_85) of the \"Notes to Condensed Consolidated Financial Statements\" for additional information on the goodwill impairment charge. The decline in Medical segment profit was due to net inflationary impacts and an adverse impact from personal protective equipment, which included inventory charges as a result of our simplification strategy.  Non-GAAP operating earnings decreased 20 percent to $423 milli","filed_date":"2022-11-04","accession":"0000721371-22-000133","full_text":"https://origin.rootz.global/static/filing/0000721371-22-000133.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":18,"context":"Business Days after the LC Bank shall have furnished the Seller a copy of such Letter of Credit and such error is material and no drawing has been made thereon prior to receipt of such notice (ix)any Material Adverse Effect (x)any breach of this Agreement or any other Transaction Document by any party thereto (xi)the bankruptcy or insolvency of any Seller Party, any Originator or any Affiliate of the foregoing (xii)the","filed_date":"2022-10-04","accession":"0000721371-22-000127","full_text":"https://origin.rootz.global/static/filing/0000721371-22-000127.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":24,"context":"sessment of Compensation Programs Management has assessed our compensation programs and concluded that our compensation policies and practices do not create risks that are reasonably likely to have a material adverse effect on Cardinal Health. This risk assessment included reviewing the design and operation of our compensation programs, identifying and evaluating situations or compensation elements that could raise more","filed_date":"2022-09-28","accession":"0001308179-22-000365","full_text":"https://origin.rootz.global/static/filing/0001308179-22-000365.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":25,"context":"LLP |  39 |  | | POLICY ON PRE-APPROVAL OF SERVICES PROVIDED BY ERNST & YOUNG LLP |  39 |  | | EXECUTIVE COMPENSATION |  40 |  | | PROPOSAL 3 &#x2014; ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS |  41 |  | | COMPENSATION DISCUSSION AND ANALYSIS |  42 |  | | HUMAN RESOURCES AND COMPENSATION COMMITTEE REPORT |  57 |  | | EXECUTIVE COMPENSATION TABLES |  57 |  | | PAY RATIO DISCLOSURE |  70 |","filed_date":"2022-09-28","accession":"0001308179-22-000365","full_text":"https://origin.rootz.global/static/filing/0001308179-22-000365.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"margin_pressure","strength":100,"match_count":21,"context":"argin | | | | | (in millions) | 2022 | | 2021 | | Change | | | Gross margin | $ | 6,545 | | | $ | 6,778 | | | (3) | % | | Fiscal 2022 Compared to Fiscal 2021  | | | | | | | | Fiscal 2022 consolidated gross margin decreased primarily due to the divestiture of the Cordis business and increased costs in the Medical segment due to net inflationary impacts and the adverse impact of global supply chain constraints, partially","filed_date":"2022-08-11","accession":"0000721371-22-000058","full_text":"https://origin.rootz.global/static/filing/0000721371-22-000058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":15,"context":"Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain medication and our efforts to resolve related claims could have additional or unexpected material negative effects on our business. Our Pharmaceutical segment distributes prescription opioid pain medications. The abuse of prescription opioid pain medication has become a public health crisis. A significant number","filed_date":"2022-08-11","accession":"0000721371-22-000058","full_text":"https://origin.rootz.global/static/filing/0000721371-22-000058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":23,"context":"Cordis business from Johnson & Johnson for $1.9 billion in October 2015. This divestiture also included Access Closure, Inc., a manufacturer and distributor of extravascular closure devices, that we acquired for approximately $320 million in May 2014.  In August 2018, we completed the sale of our equity interest in naviHealth, Inc. to investor entities controlled by Clayton, Dubilier & Rice, LLC for proceeds of $737 million","filed_date":"2022-08-11","accession":"0000721371-22-000058","full_text":"https://origin.rootz.global/static/filing/0000721371-22-000058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":17,"context":"2022, we deployed $1.0 billion for share repurchases, $597million for debt repayment, and $425 million for cash dividends. We also received proceeds of $923 million, net of cash transferred, from the divestiture of the Cordis business. | | | | | | | | | | | | | | | | | 5 | Cardinal Health | Q3 Fiscal 2022 Form 10-Q | | | | | | | | | | | | | | | MD&A | Overview | | | Significant Developments in Fiscal 2022 and T","filed_date":"2022-05-05","accession":"0000721371-22-000032","full_text":"https://origin.rootz.global/static/filing/0000721371-22-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":18,"context":"nflationary impacts, primarily related to commodities and transportation, global supply chain constraints, the adverse impact of the net positive impact of PPE in the prior year and the impact of the divestiture of the Cordis business.  | | | | | | | | | | | | | | | | | 3 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q | | | | | | | | | | | | | | | MD&A | Overview | | | GAAP and Non-GAAP Diluted EPS | | | | | | |","filed_date":"2022-02-03","accession":"0000721371-22-000013","full_text":"https://origin.rootz.global/static/filing/0000721371-22-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":16,"context":"n, we deployed cash of $587 million for early debt repayment and $500 million for share repurchases, which was partially offset by proceeds of $927 million, net of cash transferred, received from the divestiture of the Cordis business. | | | | | | | | | | | | | | | | | 4 | Cardinal Health | Q1 Fiscal 2022 Form 10-Q | | | | | | | | | | | | | | | MD&A | Overview | | | Significant Developments in Fiscal 2022 and T","filed_date":"2021-11-09","accession":"0000721371-21-000116","full_text":"https://origin.rootz.global/static/filing/0000721371-21-000116.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":29,"context":"& YOUNG LLP |  38 |  | | POLICY ON PRE-APPROVAL OF SERVICES PROVIDED BY ERNST & YOUNG LLP |  38 |  | | EXECUTIVE COMPENSATION |  39 |  | | PROPOSAL 3 ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS |  40 |  | | LETTER FROM THE HUMAN RESOURCES AND COMPENSATION COMMITTEE |  41 |  | | COMPENSATION DISCUSSION AND ANALYSIS |  43 |  | | HUMAN RESOURCES AND COMPENSATION COMMITTEE REPORT |  59 |  | |","filed_date":"2021-09-23","accession":"0001308179-21-000318","full_text":"https://origin.rootz.global/static/filing/0001308179-21-000318.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":14,"context":"Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain medication and our efforts to resolve related claims could have additional or unexpected material negative effects on our business. Our Pharmaceutical segment distributes prescription opioid pain medications. In recent years, the abuse of prescription opioid pain medication has become a public health crisis. A s","filed_date":"2021-08-16","accession":"0000721371-21-000080","full_text":"https://origin.rootz.global/static/filing/0000721371-21-000080.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":18,"context":"Cordis business from Johnson & Johnson for $1.9 billion in October 2015. This divestiture also includes Access Closure, Inc., a manufacturer and distributor of extravascular closure devices, that we acquired for approximately $320 million in May 2014.  In August 2018, we completed the sale of our equity interest in naviHealth, Inc. to investor entities controlled by Clayton, Dubilier & Rice, LLC (\"CD&R\") for proceeds of $73","filed_date":"2021-08-16","accession":"0000721371-21-000080","full_text":"https://origin.rootz.global/static/filing/0000721371-21-000080.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"y make base payments equal to fifty-five percent (55%) of the Net Abatement Amount multiplied by the aggregate Overall Allocation Percentage of the Settling States. These payments will be due in installments consistent with Exhibit M over the eighteen (18) Payment Years and as adjusted by the Settlement Fund Administrator pursuant to the provisions in Section IV, Section XII, and Section XIII.  17  F","filed_date":"2021-07-22","accession":"0001193125-21-221339","full_text":"https://origin.rootz.global/static/filing/0001193125-21-221339.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":16,"context":"Fiscal 2021 Form 10-Q | | | | | | | | | | | | | | | MD&A | Overview | | | Significant Developments in Fiscal 2021 and Trends Cordis Divestiture | | | | | | | | On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we will retain certain working capital accounts and certai","filed_date":"2021-05-06","accession":"0000721371-21-000041","full_text":"https://origin.rootz.global/static/filing/0000721371-21-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":30,"context":"& Young LLP |  29 |  | | Policy on Pre-Approval of Services Provided by Ernst & Young LLP |  29 |  | | Executive Compensation |  30 |  | | Proposal 3  Advisory Vote to Approve the Compensation of Our Named Executive Officers |  30 |  | | Compensation Discussion and Analysis |  31 |  | | Human Resources and Compensation Committee Report |  39 |  | | Executive Compensation Tables |  40 |  | | Pay Ratio Disclosure |  50 |","filed_date":"2020-09-23","accession":"0001308179-20-000273","full_text":"https://origin.rootz.global/static/filing/0001308179-20-000273.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":13,"context":"margins could be adversely affected. The public health crisis involving the abuse of prescription opioid pain medication and our efforts to resolve related claims could have additional or unexpected material negative effects on our business. Our Pharmaceutical segment distributes prescription opioid pain medications. In recent years, the abuse of prescription opioid pain medication has become a public health crisis. A s","filed_date":"2020-08-13","accession":"0000721371-20-000089","full_text":"https://origin.rootz.global/static/filing/0000721371-20-000089.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":24,"context":"& Young LLP |  28 |  | | Policy on Pre-Approval of Services Provided by Ernst & Young LLP |  28 |  | | Executive Compensation |  29 |  | | Proposal 3  Advisory Vote to Approve the Compensation of Our Named Executive Officers |  29 |  | | Compensation Discussion and Analysis |  30 |  | | Human Resources and Compensation Committee Report |  38 |  | | Executive Compensation Tables |  38 |  | | Pay Ratio Disclosure |  48 |","filed_date":"2019-09-20","accession":"0001308179-19-000231","full_text":"https://origin.rootz.global/static/filing/0001308179-19-000231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":13,"context":"by manufacturers or customers for the value of our services, our margins could be adversely affected. The public health crisis involving the abuse of prescription opioid pain medication could have a material negative effect on our business. Our Pharmaceutical segment distributes prescription opioid pain medications. In recent years, the abuse of prescription opioid pain medication has become a public health crisis.  A s","filed_date":"2019-08-20","accession":"0000721371-19-000090","full_text":"https://origin.rootz.global/static/filing/0000721371-19-000090.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":10,"context":"xecutive officers describe positions held during the last five years (unless otherwise indicated). Mr.Kaufmann has served as Chief Executive Officer since January 2018 and in August 2019, he was also appointed to serve as Interim Chief Financial Officer. From November 2014 through December 2017, he served as Chief Financial Officer. From August 2009 until November 2014, he served as Chief Executive Officer, Pharmaceutical segment.","filed_date":"2019-08-20","accession":"0000721371-19-000090","full_text":"https://origin.rootz.global/static/filing/0000721371-19-000090.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":25,"context":"modifications or supplements thereto or waivers thereof. Material Acquisition means the Acquisition by the Company or one of its Subsidiaries for aggregate cash consideration of $500,000,000 or more. Material Adverse Effect means a material adverse effect on (a) the condition (financial or otherwise) or results of operations of the Company and its Subsidiaries taken as a whole, (b) the ability of the Company to perform","filed_date":"2019-06-28","accession":"0000721371-19-000042","full_text":"https://origin.rootz.global/static/filing/0000721371-19-000042.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":22,"context":"& Young LLP |  25 |  | | Policy on Pre-Approval of Services Provided by Ernst & Young LLP |  25 |  | | Executive Compensation |  26 |  | | Proposal 3 Advisory Vote to Approve the Compensation of Our Named Executive Officers |  26 |  | | Compensation Discussion and Analysis |  27 |  | | Human Resources and Compensation Committee Report |  34 |  | | Executive Compensation Tables |  35 |  | | Pay Ratio Disclosure |  48 |","filed_date":"2018-09-26","accession":"0001308179-18-000266","full_text":"https://origin.rootz.global/static/filing/0001308179-18-000266.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":15,"context":"To ratify the appointment of Ernst & Young LLP as our independent auditor for the fiscal year ending June 30, 2018; | | | | (3) | To approve, on a non-binding advisory basis, the compensation of our named executive officers; | | | | (4) | To vote, on a non-binding advisory basis, on the frequency of future advisory votes to approve executive compensation; | | | | (5) | To vote on two shareholder proposals described in","filed_date":"2017-09-21","accession":"0000721371-17-000124","full_text":"https://origin.rootz.global/static/filing/0000721371-17-000124.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":11,"context":"siness in which it is engaged in each jurisdiction or place where the conduct of its business requires such licenses or qualification and where the failure to be so licensed or qualified would have a material adverse effect on the business or financial condition of the Company and its subsidiaries taken as a whole (a **Material Adverse Effect**).  (j) Each of the Companys significant subsidiaries (as defined in Rule 1-0","filed_date":"2017-06-05","accession":"0001193125-17-193660","full_text":"https://origin.rootz.global/static/filing/0001193125-17-193660.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":20,"context":"year ending June 30, 2017; | | | | (3) | To approve the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan; | | | | (4) | To approve, on a non-binding advisory basis, the compensation of our named executive officers; and | | | | (5) | To transact such other business as may properly come before the meeting or any adjournment or postponement. | | | Who may vote: | Shareholders of record at the close of business o","filed_date":"2016-09-16","accession":"0000721371-16-000305","full_text":"https://origin.rootz.global/static/filing/0000721371-16-000305.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":27,"context":"modifications or supplements thereto or waivers thereof. Material Acquisition means the Acquisition by the Company or one of its Subsidiaries for aggregate cash consideration of $500,000,000 or more. Material Adverse Effect means a material adverse effect on (a) the condition (financial or otherwise) or results of operations of the Company and its Subsidiaries taken as a whole, (b) the ability of the Company to perform","filed_date":"2016-06-21","accession":"0000721371-16-000240","full_text":"https://origin.rootz.global/static/filing/0000721371-16-000240.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":15,"context":"To ratify the appointment of Ernst & Young LLP as our independent auditor for the fiscal year ending June 30, 2016; | | | | (3) | To approve, on a non-binding advisory basis, the compensation of our named executive officers; and | | | | (4) | To transact such other business as may properly come before the meeting or any adjournment or postponement. | | | Who may vote: | Shareholders of record at the close of business o","filed_date":"2015-09-15","accession":"0000721371-15-000143","full_text":"https://origin.rootz.global/static/filing/0000721371-15-000143.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":11,"context":"siness in which it is engaged in each jurisdiction or place where the conduct of its business requires such licenses or qualification and where the failure to be so licensed or qualified would have a material adverse effect on the business or financial condition of the Company and its subsidiaries taken as a whole (a Material Adverse Effect).  (j) Each of the Companys significant subsidiaries (as defined in Rule 1-02 of","filed_date":"2015-06-23","accession":"0001193125-15-232063","full_text":"https://origin.rootz.global/static/filing/0001193125-15-232063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CAH","company":"CARDINAL HEALTH INC","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":15,"context":".18 of this Agreement to be true and correct on the date hereof and at and as of the Applicable Closing Date (the amount of such Taxes determined without references to the terms material, materially, Material Adverse Effect, material adverse effect or other similar qualifications as to materiality (including specific monetary thresholds) contained or incorporated in any such representation or warranty, but such qualific","filed_date":"2015-05-28","accession":"0001193125-15-202868","full_text":"https://origin.rootz.global/static/filing/0001193125-15-202868.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"ede595d745cb53703e8adf82ceab0e2569442cd2e7b4fd22fa64bcfd30baa9e2","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"b689827a131031bf0ad5cd489df2c1202ae2d5bd0d15a217d698bc82cc1d59a7","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":70,"hourly_limit":500,"remaining":430,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}